Anales del sistema sanitario de Navarra最新文献_第6页

[Morbi-mortality of lower respiratory tract infections and vaccination]. [下呼吸道感染的死亡率与疫苗接种]。

Anales del sistema sanitario de Navarra Pub Date : 2023-12-26 DOI: 10.23938/ASSN.1063

Manuel García Cenoz, Iván Martínez Baz

引用次数: 0

[Nirmatrelvir/ritonavir drug-drug interactions in primary care outpatients]. [初级保健门诊患者中的尼马瑞韦/利托那韦药物相互作用]。

Anales del sistema sanitario de Navarra Pub Date : 2023-12-26 DOI: 10.23938/ASSN.1056

Andrea Rodríguez Esquíroz, Lorea Sanz Álvarez, Marta Marín Marín, Patricia García González, Paula Aldave Cobos, Javier Garjón Parra

{"title":"[Nirmatrelvir/ritonavir drug-drug interactions in primary care outpatients].","authors":"Andrea Rodríguez Esquíroz, Lorea Sanz Álvarez, Marta Marín Marín, Patricia García González, Paula Aldave Cobos, Javier Garjón Parra","doi":"10.23938/ASSN.1056","DOIUrl":"10.23938/ASSN.1056","url":null,"abstract":"Background: The oral antiviral nirmatrelvir/ritonavir interacts with a range of drugs. Candidate patients to receive this antiviral agent are usually vulnerable, multipathological and polymedicated. The objective is to evaluate the pharmaceutical validation prior to the administration of the antiviral.Material and methods: Drug-drug interactions between nirmatrelvir/ritonavir and patients' usual treatment medications were checked in product information and in the UpToDate® and the University of Liverpool® interaction tools. We included validated prescriptions between April/2022 and April/2023 by a Primary Care pharmacist.Results: Of the 159 study patients, 168 interactions were found in 83 individuals, which may have led to changes of their usual treatment. Statins (25.6%), anticoagulants (10.7%), and antihypertensives (10.7%) were the most frequently implicated therapeutic groups. Discontinuation (53.0%) and dose reduction (22.6%) were the most common treatment changes.Conclusions: Our search of potential drug interactions and subsequent dose adjustments and modifications of the patient's usual treatment has helped avoid potential toxicities ensuring a safe use of nirmatrelvir/ritonavir.","PeriodicalId":500996,"journal":{"name":"Anales del sistema sanitario de Navarra","volume":"46 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10807205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139038376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Relationship between treatment and cost with visual acuity improvementin age-related macular degeneration]. [老年性黄斑变性视力改善的治疗与成本关系]。

Anales del sistema sanitario de Navarra Pub Date : 2023-11-27 DOI: 10.23938/ASSN.1052

Josep-Oriol Casanovas-Marsal, Elisa Viladés Palomar, Francisco de Asís Bartol-Puyal, Rubén Hernández Vian, Luis E Pablo Júlvez

{"title":"[Relationship between treatment and cost with visual acuity improvement\u0000in age-related macular degeneration].","authors":"Josep-Oriol Casanovas-Marsal, Elisa Viladés Palomar, Francisco de Asís Bartol-Puyal, Rubén Hernández Vian, Luis E Pablo Júlvez","doi":"10.23938/ASSN.1052","DOIUrl":"10.23938/ASSN.1052","url":null,"abstract":"Background: We examined the relationship between visual acuity changes (VA) and the cost of care and treatment with anti-vascular endothelial growth factors (antiVEGF) in patients diagnosed with age-related exudative macular degeneration (exudative AMD).Methods: Observational, longitudinal, retrospective study of patients ≥50 years of age diagnosed with exudative AMD, with a log-MAR VA between 0.6 and 0.06. and 0.06. Follow-up and treatment were done in our tertiary hospital between January 1, 2014 and December 31, 2018.Results: The study included 778 patients; 62.2% female and mean age 79.83±7.94 years; 957 eyes had exudative AMD. Mean of final VA (0.65±0.45) increasing 3.2% compared to initial values. Ranibizumab was administered to 60.3% of the eyes, aflibercept to 10.2% and ranibizumab + aflibercept (mixed group) to 29.5%. Significant increase in VA was seen in the group with the mixed treatment, with no inter-group differences. Although follow-up/treatment was longer for the mixed group, they received fewer anti-VEGF injections and optical coherence tomography (OCT). The total expenditure per year and treated eye was € 1,972.7±824.5; costs were higher for visit, OCT, and treatment in the aflibercept group, and lower for fluorescein angiography, antiVEGF treatment, and total costs in the mixed group. Decimal VA gain had a cost of € 872±1,077.7 with no significant inter-group differences.Conclusions: AntiVEGF treatments (ranibizumab, aflibercept, or both) maintained VA in patients with exudative AMD. Overall, care and treatment costs were lower in the group that received both drugs.","PeriodicalId":500996,"journal":{"name":"Anales del sistema sanitario de Navarra","volume":"46 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10783600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138441956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of a cardiac rehabilitation program in a municipal sports center compared to the hospital program: randomized controlled trial eCARCEX. [市政体育中心心脏康复方案与医院方案的疗效比较:随机对照试验eCARCEX]。

Anales del sistema sanitario de Navarra Pub Date : 2023-11-24 DOI: 10.23938/ASSN.1050

Juan Izquierdo-García, Adrián Arranz-Escudero, Rocío Tello de Meneses, Noelia De la Torre, Isabel M Amat-Macías, Juan I Castillo Martín, M Paz Sanz-Ayán, Guillermo Moreno

{"title":"Efficacy of a cardiac rehabilitation program in a municipal sports center compared to the hospital program: randomized controlled trial eCARCEX.","authors":"Juan Izquierdo-García, Adrián Arranz-Escudero, Rocío Tello de Meneses, Noelia De la Torre, Isabel M Amat-Macías, Juan I Castillo Martín, M Paz Sanz-Ayán, Guillermo Moreno","doi":"10.23938/ASSN.1050","DOIUrl":"10.23938/ASSN.1050","url":null,"abstract":"Background: This study aimed to analyze the effects of an outpatient cardiac rehabilitation program in a municipal sports center on functional capacity and adherence to physical exercise - among other variables - compared to an in-hospital program.Methods: Randomized clinical trial that included two parallel groups of acute coronary syndrome patients who performed a cardiac rehabilitation program that consisted of moderate physical exercise intervals along with learning healthy habits in a municipal sports center (experimental group) and in a tertiary hospital (control group) between September 2019 and June 2020. We collected the following data: compliance, anthropometrical, clinical, psychological variables, diet and tobacco habits, strength and functional capacity from ergospirometry.Results: Twenty-two patients completed the cardiac rehabilitation program (experimental group=12, control group=10). Significant improvement was observed for cholesterol, the sit-and-stand test, cardiac frequency in VT1 and VT2, and watts in VT1 in the control group, and for HDL-cholesterol, triglycerides, the sit-and-stand test, and frequency, and watts in VT1 in the experimental group. Better achievement was found in the control group for cardiac frequency in VT2 (11.17 vs 2.88 bpm) and in EG for HDL-cholesterol (11.0 vs 0.63 mg/dL).Conclusions: We are unable to determine the effectiveness of the out-of-hospital cardiac rehabilitation program due to a lack of power (high number of withdrawals caused by COVID-19 lockdown). However, the experimented group achieved higher HDL-cholesterol levels, while cardiac frequency in VT2 was higher in the control group.","PeriodicalId":500996,"journal":{"name":"Anales del sistema sanitario de Navarra","volume":"46 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10750805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138300941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful outpatient conservative management of chyle leak after laparoscopic left hemicolectomy. 腹腔镜左结肠切除术后乳糜漏的成功保守治疗。

Anales del sistema sanitario de Navarra Pub Date : 2023-11-22 DOI: 10.23938/ASSN.1051

Laura Rubio López, Silvia Benito Barbero, Javier Páramo Zunzunegui, Teresa Antón Bravo, Maria Moral Gonzalez

引用次数: 0

[Autologous hematopoietic stem cell transplantation in a patient with refractory Crohn's disease]. 自体造血干细胞移植治疗难治性克罗恩病1例

Anales del sistema sanitario de Navarra Pub Date : 2023-11-15 DOI: 10.23938/ASSN.1054

Ana Gordo Ortega, Maren Eizaguirre Ubegun, Martín Balerdi Trébol, Saioa Rubio Iturria, Cristina Rodríguez Gutiérrez

引用次数: 0

[Management of membranoproliferative glomerulonephritis secondary to infection by hepatitis C virus]. [丙型肝炎病毒感染继发膜增生性肾小球肾炎的治疗]。

Anales del sistema sanitario de Navarra Pub Date : 2023-11-15 DOI: 10.23938/ASSN.1055

Ignacio Lasierra Lavilla, Amalia Perona Caro, Celia Del Agua Arias-Camisón, Julien Paola Caballero Castro

引用次数: 0